Evidence map›Paper›PMID 19454669›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2009

Cooperation between molecular targets of costimulation in promoting T cell persistence and tumor regression.

Baohua Zhao, Aihua Song, Rizwanul Haque, Fengyang Lei, Lauren Weiler, Xiaofang Xiong, Yuzhang Wu, Michael Croft, Jianxun Song

Open access · greenAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Baohua ZhaoDepartment of Microbiology and Immunology and Pennsylvania State Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Aihua Song
Rizwanul Haque
Fengyang Lei
Lauren Weiler
Xiaofang Xiong
Yuzhang Wu
Michael Croft
Jianxun Song
Pennsylvania State University · USLa Jolla Institute for Immunology · USPenn State Milton S. Hershey Medical Center · USArmy Medical University · CNHebei Normal University · CN

Funding

The Molecular Basis of OX40 on CD4 T CellsR01AI049453 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL · 2003 to 2012
$3.9M
Regulation of T Cell Tolerance by OX40R01CA091837 · NCI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL · 2002 to 2012
$2.5M
NCI NIH HHS CA91837NCI NIH HHS R01 CA091837NIAID NIH HHS AI49453NIAID NIH HHS R01 AI049453
6 · The paper itself

Abstract

Costimulation regulates multiple cellular processes of T cells inducing proliferation, expansion, and survival. The molecular targets of costimulation might then be useful to augment T cell activities. Two defined targets of costimulatory signals in primary T cells are the anti-apoptotic bcl-2 family molecule Bcl-x(L), and survivin, an inhibitor of apoptosis family member that might regulate both cell division and survival. However, the relative importance of, and relationship between, these molecules in primary T cells is not clear. To understand whether they have overlapping or cooperative functions, we used retrovirus-mediated transduction to introduce Bcl-x(L) and survivin separately, or together linked by a 2A picornavirus self-cleaving peptide, into Ag-responding CD8(+) T cells. We found that CD8(+) effector T cells expressing both Bcl-x(L) and survivin strongly expanded at an early stage and had a long-term survival advantage over cells transduced with either molecule alone. In vivo, with response to tumor-expressed Ag following adoptive T cell transfer, Ag-reactive CD8(+) T cells expressing both Bcl-x(L) and survivin displayed greatly enhanced tumor protective activity compared with CD8(+) T cells expressing either molecule introduced separately. These results indicate that Bcl-x(L) and survivin can critically contribute in a cooperative, nonredundant manner to augment the accumulation and persistence of CD8(+) T cells following encounter with Ag. The data provide new insights into why costimulatory signals might need to be sustained over time and suggest a potential novel approach to augment cellular immunotherapy for cancer.

Indexed as

AnimalsAntigensApoptosis Regulatory Proteinsbcl-X ProteinCD8-Positive T-LymphocytesCross-Linking ReagentsInhibitor of Apoptosis ProteinsLymphocyte ActivationMiceMice, TransgenicMicrotubule-Associated ProteinsNeoplasmsRepressor ProteinsSurvivinTransduction, GeneticAntigensApoptosis Regulatory Proteinsbcl-X ProteinBirc5 protein, mouseCross-Linking ReagentsInhibitor of Apoptosis ProteinsMicrotubule-Associated ProteinsRepressor ProteinsSurvivin

Identifiers

PMID19454669
PMCPMC2748393
OpenAlexW2100299351

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.